Payment overview · 2025
General Payments
$551.94
24 reported records · 9 companies
Healthcare provider profile · identity verified
Suman Lamsal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAYBORO, NC · NPI 1235179698
Verified facts
What the public records show
CMS Open Payments records show Suman Lamsal, MD received $551.94 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.05 | 25.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $80.68 | 14.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.13 | 14.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.99 | 11.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.06 | 11.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $54.14 | 9.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.46 | 5.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.27 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.16 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $551.94 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.05 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $107.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $80.68 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $80.13 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $54.14 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.50 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.46 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.46 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 551 | 143 |
| Metformin Hcl | Metformin Hcl | 510 | 103 |
| Gabapentin | Gabapentin | 492 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 460 | 112 |
| Omeprazole | Omeprazole | 457 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 72 |
| Losartan Potassium | Losartan Potassium | 335 | 74 |
| Furosemide | Furosemide | 312 | 72 |
| Trazodone Hcl | Trazodone Hcl | 284 | 62 |
| Potassium Chloride | Potassium Chloride | 274 | 56 |
| Eliquis | Apixaban | 272 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 41 |
| Alprazolam | Alprazolam | 221 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 46 |
| Montelukast Sodium | Montelukast Sodium | 216 | 45 |
| Mirtazapine | Mirtazapine | 206 | 38 |
| Lisinopril | Lisinopril | 203 | 52 |
| Prednisone | Prednisone | 190 | 105 |
| Meloxicam | Meloxicam | 186 | 49 |
| Ozempic | Semaglutide | 186 | 33 |
| Carvedilol | Carvedilol | 161 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 153 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 30 |
| Famotidine | Famotidine | 135 | 35 |
| Farxiga | Dapagliflozin Propanediol | 131 | 27 |
| Simvastatin | Simvastatin | 130 | 30 |
| Finasteride | Finasteride | 127 | 22 |
| Tramadol Hcl | Tramadol Hcl | 126 | 52 |
| Allopurinol | Allopurinol | 125 | 30 |
| Donepezil Hcl | Donepezil Hcl | 124 | 20 |
| Lorazepam | Lorazepam | 124 | 26 |
| Alendronate Sodium | Alendronate Sodium | 123 | 33 |
| Metformin Hcl Er | Metformin Hcl | 119 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 30 |
| Jardiance | Empagliflozin | 116 | 16 |
| Sertraline Hcl | Sertraline Hcl | 106 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 35 |
| Spironolactone | Spironolactone | 91 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 27 |
| Cefuroxime | Cefuroxime Axetil | 86 | 70 |
| Januvia | Sitagliptin Phosphate | 79 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 27 |
| Memantine Hcl | Memantine Hcl | 76 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 19 |
| Chlorthalidone | Chlorthalidone | 67 | 13 |
| Baclofen | Baclofen | 66 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | suppressed |
| Trulicity | Dulaglutide | 62 | suppressed |
| Telmisartan | Telmisartan | 61 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | suppressed |
| Myrbetriq | Mirabegron | 58 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 57 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Valsartan | Valsartan | 57 | 14 |
| Clonazepam | Clonazepam | 54 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Glipizide | Glipizide | 49 | 11 |
| Pregabalin | Pregabalin | 48 | 15 |
| Ramipril | Ramipril | 48 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 15 |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Glimepiride | Glimepiride | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Verapamil Er | Verapamil Hcl | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Atenolol | Atenolol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 19 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 16 |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 11 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $551.94 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, FARXIGA, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error